Nyxoah is expected to report a Q3 2026 loss of €0.24 per share on revenue of €9.2 million, with its stock currently trading at $0.87 against a consensus analyst price target of $4.20.
Investors are primarily focused on the commercial momentum of the Genio sleep apnea system in the U.S. market following its regulatory approval and subsequent launch.
Preliminary results released in October indicate U.S. net revenue reached €6.7 million, representing a 29% sequential increase and reflecting a healthy ramp-up in account activations.
However, a recent reduction in full-year 2026 guidance has placed greater emphasis on management's commentary regarding surgeon training rates and the progress of the FDA PMA supplement for expanded patient indications.